PAC fixed dose: Pharmacokinetics of a 1-hour paclitaxel infusion and comparison to BSA-normalized drug dosing

Onkologie

Volumn 29, Issue 10, 2006, Pages 444-450

  Mross, Klaus ^a   Holländer, Norbert ^b   Frost, Annette ^a   Unger, Clemens ^a   Ziroli, Vittorio ^a   Massing, Ulrich ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Fixed dose; Paclitaxel; Pharmacokinetics

Indexed keywords

PACLITAXEL;

ADULT; ADVANCED CANCER; AREA UNDER THE CURVE; ARTICLE; BODY SURFACE; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INFUSION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; PARAMETER; PLASMA CLEARANCE; QUANTITATIVE ANALYSIS; STEADY STATE;

ADULT; ANTINEOPLASTIC AGENTS; BODY SURFACE AREA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASMS; PACLITAXEL;

EID: 33749370865     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000095243     Document Type: Article

References (40)

1. Rosenthal DI, Lee JH, Sinard R, Yardley DA, Machtay M, Rosen DM, Egorin MJ, Weber RS, Weinstein GS, Chalian AA, Miller LK, Frenkel EP, Carbone DP: Phase I study of paclitaxel given by seven-week continuous infusion concurrent with radiation therapy for locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol 2001;19:1363-1373.
2. Spriggs DR, Tondini C: Taxol administered as a 120 hour infusion. Invest New Drugs 1992;10:275-278.
3. Berg SL, Cowan KH, Balis FM, Fisherman JS, Denicoff AM, Hillig M, Poplack DG, O'Shoughnessy JA: Pharmacokinetics of Taxol and doxorubicin administered alone and in combination by continuous 72-hour infusion. J Natl Cancer Inst 1994;86:143-145.
4. Wiernick PH, Schwartz EL, Einzig A, Strauman JJ, Lipton RB, Dutcher JP: Phase I trial of Taxol given as 24-hour infusion every 21 days: Responses observed in metastatic melanoma. J Clin Oncol 1987;5:1232-1239.
5. Wiernick PH, Schwartz EL, Strauman JJ, Dutcher JP, Lipton RB, Paietta E: Phase I clinical trial and pharmacokinetic study of Taxol. Cancer Res 1987;47:2486-2493.
6. Seidman AD, Tiersten A, Hudis C, Gollup M, Barrett S, Yao TJ, Lepore J, Gilewski T, Currie V, Crown J, Hakes T, Baselga J, Skalrin N, Moynikan ME, Tong W, Egorin M, Kearns C, Spriggs D, Norton L: Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol 1995;13:2575-2581.
7. Hainsworth JD, Greco FA: Paclitaxel administered by 1-hour infusion. Cancer 1994;74:1377-1382.
8. Grem JL, Tutsch KD, Simon KJ, Alberti DB, Willson JK, Tormey DC: Phase I study of Taxol administered as a short intravenous infusion daily for 5 days. Cancer Treat Rep 1987;71:1179-1181.
9. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, Gianni L, Myles J, van der Burg MEL, Kerr I, Vermorken JB, Buser K, Colombo N, Bacon M, Santabarbara P, Onetto N, Winograd B, Canetta R: European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 1994;12:2654-2666.
10. Mross K, Hauns B, Häring B, Bauknecht T, Meerpohl HG, Unger C, Maier-Lenz H: Clinical phase I study with one-hour infusion. Ann Oncol 1998;9:569-572.
11. Gianni L, Kearns CM, Giani A, Capri G, Vigano L, Locatelli A, Bonodonna G, Egorin MJ: Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationship in humans. J Clin Oncol 1995;13:180-190.
12. Kearns CM, Gianni L, Egorin M: Paclitaxel pharmacokinetics and pharmacodynamics. Sem Oncol 1995;22(suppl 6):16-23.
13. Huizing MT, Keung ACF, Rosing H, van der Kuij V, ten Bokkel Huinink WW, Mandjes IM, Dubbelman AC, Pinedo HM, Beijnen JH: Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol 1993;11:2127-2135.
14. Mross K, Holländer N, Hauns B, Schumacher M, Maier-Lenz H: The pharmacokinetics of a 1-h paclitaxel infusion. Cancer Chemother Pharmacol 2000;45;463-470.
15. D'Addario G, Morant R, Böhme C, Cerny T: Feasibility and toxicity of weekly paclitaxel-carboplatin in 131 patients pretreated and non-pretreated solid tumors. Onkologie 2002;25:152-157.
16. Markman M, Hall J, Spitz D, Weiner S, Carson L, Van Le L, Baker M: Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. J Clin Oncol 2002;20:2365-2369.
17. Mross K, Häring B, Holländer N, Mielke S, Behringer D, Massing U, Unger C: Comparison of 1-hour and 3-hour paclitaxel infusion pharmacokinetics: results from a randomized trial. Onkologie 2002;25;503-508.
18. Mielke S, Mross K, Gerds TA, Schmidt A, Wäsch R, Berger DP, Lange W, Behringer D: Comparative neurotoxicity of weekly non-break paclitaxel infusions over 1 versus 3 h. Anti-Cancer Drugs 2003;14;785-792.
19. Seidman AD, Berry D, Cirrincione C, Harris L, Dressler L, Naughton M, Norton L, Winer E, Hudis C: CALGB 9840: phase III study of weekly paclitaxel via 1-hour infusion versus standard 3-hour infusion every third week in the treatment of metatstatic breast cancer (MBC), with trastuzumab for HER2 positive MBC and randomized for traztuzumab in HER2 normal MBC. J Clin Oncol 2004;22(14S):512.
20. Miller AA, Rosner GL, Egorin MJ, Hollis D, Lichtman SM, Ratain MJ: Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors: CALGB study 9763. Clin Cancer Res 2004;10:8325-8331.
21. Willey TA, Bekos EJ, Gaver RC, Duncan GF, Tay LK, Beijnen JH, Farmen RH: High performance liquid chromatographic procedure for the quantitative determination of paclitaxel (Taxol) in human plasma. J Chromatogr 1993;621:231-238.
22. Wagner JG, Searle J: Pharmacokinetics for the Pharmacoceutical Scientist. Lancaster, Technomic Publ, 1993.
23. Gibaldi M: Biopharmaceutics and Clinical Pharmacokinetics, 3rd ed. Philadelphia, Lea & Febiger, 1984.
24. Bailer AJ, Piegorsch WW: Estimating integrals using quadrature methods with an application in pharmacokinetics. Biometrics 1980;46:1201-1211.
25. Fisher LD, van Belle G: Biostatistics: A Methodology for the Health Sciences. New York, Wily, 1993.
26. SAS Institute Inc: SAS/STAT User's Guide, version 6, 4th ed. SAS Institute Inc., Cary, NC, 1989.
27. Philip H, Schwartz CP: The application of BASE SAS, SAS/STAT, and SAS/GRAPH software to the analysis and presentation of pharmacokinetic data. Proc SAS Users Group International Conference 1989;14:1168-1172.
28. Gelderblom H, Mross K, ten Tije A, Behringer D, Mielke S, van Zomeren DM, Verweij J, Sparreboom A: Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions. J Clin Oncol 2002;20:574-581.
29. Rowinsky EK, Burke PJ, Karp JE, Tucker RW, Ettinger DS, Donehower RC: Phase I and pharmacodynamic study of Taxol in refractory acute leukemias. Cancer Res 1989;49:4640-4647.
30. 2 continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer. Cancer Chemother Pharmacol 2001;47:45-50.
31. Weiss R, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, Baker JR, van Echo DA, von Hoff DD, Leyland-Jones B: Hypersensitivity reactions from Taxol. J Clin Oncol 1990;8:1263-1268.
32. Tsavaris NB, Kosmas C: Risk of severe acute hypersensitivity reactions after rapid paclitaxel infusion of less than 1-h duration. Cancer Chemother Pharmacol 1998;42:509-511.
33. Beijnen JH, Huizing MT, ten Bokkel Huinink WW, Veenhoff CHN, Vermorken JB, Giaccone G, Pinedo HM: Bioanalysis, pharmacokinetics, and pharmacodynamics of the novel anticancer drug paclitaxel (Taxol). Sem Oncol 1994;21:53-62.
34. Mielke S, Sparreboom A, Steinberg S, Gelderblom H, Unger C, Behringer D, Mross K: Association of paclitaxel pharmacokinetics with the development of a peripheral neuropathy in patients with advanced cancer. Clin Cancer Res 2005;11:4843-4850.
35. Mielke S, Sparreboom A, Behringer D, Mross K.: Paclitaxel pharmacokinetics and response to chemotherapy in patients with advanced disease. Anticancer Res 2005;25:4423-4428.
36. Trudeau M, Sinclair SE, Clemons M: Neoadjuvant taxanes in the treatment of non-metastatic breast cancer: a systematic review. Cancer Treat Rev 2005;31:283-302.
37. Mross K: Die Normierung einer Chemotherapie mittels Kö rperoberfläche sollte abgeschafft werden. InFoOnkologie 1999;2:368-369.
38. Mross K: Antiangiogenesis therapy: concepts and importance of dosing schedules in clinical trials. Drug Resist Updat 2000;3:223-235.
39. Saito K, Kikuchi Y, Jujii K, Kita T, Furuya K: Effect of paclitaxel on vascular endothelial growth factor (VEGF) and interleukin (IL)-8 in serum of patients with recurrent ovarian cancer: a comparison of weekly vs. three-weekly regimens. Targ Oncol 2006;1:86-89.
40. Mielke S, Sparreboom A, Mross K: Peripheral neuropathy: a persisting challenge in paclitaxel-based regimens. Eur J Cancer 2006;42:24-30.